0 Items
Select Page

Vaccinia

Vaccinia virus is known for its use in smallpox vaccination, but following the eradication of smallpox, routine vaccination is no-longer performed. Recent interest in Vaccinia has centred on its potential use as a vector for immunization against other viruses, with a focus on developing less virulent strains than those used for vaccination against smallpox.

The Native Antigen Company offers a recombinant Vaccinia protein that demonstrates biological activity as a Type I IFN receptor.

Vaccinia Virus Background

Vaccinia virus is a large, complex, enveloped virus, belonging to the Poxvirus family. Poxviruses are unique among DNA viruses, as they replicate only in the cytoplasm of the host cell, outside of the nucleus. Therefore, a large genome is required for encoding various enzymes and proteins involved in viral DNA replication and gene transcription. The close similarity of the Vaccinia virus to smallpox virus led to its use as a vaccination to prevent smallpox. Infection by Vaccinia in healthy individuals is generally asymptomatic, but may present with a mild fever and rash. It does, however, produce lasting immunity against other pox viruses, including smallpox. Vaccinia virus has therefore been used as a live vaccine against smallpox, and although now not widely used, it remains in use for healthcare workers, the US military, and researchers working with pox viruses. The use of the vaccine is associated with very rare but severe side-effects, primarily in immunocompromised individuals.

Vaccinia Antigens

We offer recombinant Vaccinia virus B18R protein, which contains two Ig-like C2-type domains and one Ig-like V-type domain. Vaccinia virus B18R exists in a soluble and membrane-bound form. As a type I IFN receptor, B18R counteracts the antiviral effects of host IFN-alpha/beta. The B18R protein also acts as a soluble IFN-alpha receptor and thus, inhibits the interaction between host IFN-alpha and its receptor. B18R was recently shown to enable increased cell viability during RNA transfection protocols, designed to convert human somatic donor cells into iPSCs.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

The Bumpy Road to a Cytomegalovirus Vaccine

The development of a cytomegalovirus vaccine has been 50 years in the making. Are there any technologies in the pipeline that could prompt a breakthrough? This article was originally posted online at The Medicine Maker, a Texere publication.To say that...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

15 + 13 =

Live Customer Feedback

Join our mailing list

* indicates required